Atlas FDA

ELECSYS ANTI-HCV II IMMUNOASSAY

FDA premarket approval P140021/S002 · decided 2016-04-12

Approval details

PMA number
P140021
Supplement
S002
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
ELECSYS ANTI-HCV II IMMUNOASSAY
Generic name
Assay, enzyme linked immunosorbent, hepatitis c virus
Applicant
Roche Diagnostics Operations, Inc.
Date received
2015-12-17
Decision date
2016-04-12
Days to decision
117 days
Decision code
APPR
Product code
MZO
Advisory committee
Microbiology
Expedited review
No
Location
Indianapolis, IN
Statement
Approval for the migration of claims from the FDA approved Elecsys Anti-HCV II Immunoassay and Elecsys PreciControl Anti-HCV on the cobas e 601 immunoassay analyzer to the cobas e 602 analyzer. The device, as modified, will be marketed under the trade name Elecsys Anti-HCV II Immunoassay and Elecsys PreciControl Anti-HCV and is indicated for: Elecsys Anti-HCV II Immunoassay: Immunoassay for the in vitro qualitative detection of antibodies to hepatitis C virus (HCV) in human adult and pediatric (

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
ACCU-CHEK AVIVA EXPERT BLOOD GLUCOSE MONITORING SYSTEM (K131366)Roche Diagnostics Operations, Inc.2013-10-11
ACCU-CHEK AVIVA PLUS TEST STRIP (K131029)Roche Diagnostics Operations, Inc.2013-08-09